Komipharm International Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 13, 2022 at 03:20 am EDT
Share
Komipharm International Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 558.85 million compared to KRW 232.12 million a year ago. Net loss was KRW 97.85 million compared to net income of KRW 958.97 million a year ago. Basic loss per share from continuing operations was KRW 2 compared to basic earnings per share from continuing operations of KRW 15 a year ago. Diluted loss per share from continuing operations was KRW 2 compared to diluted earnings per share from continuing operations of KRW 15 a year ago. Basic loss per share was KRW 2 compared to basic earnings per share of KRW 15 a year ago.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
KOMIPHARM INTERNATIONAL CO., LTD. 
